SOLARA705.85

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹3,142 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-60.580.05-0.59-0.59
Return on Assets-24.120.02-0.32-0.32
Return on Capital Employed-17.918.316.056.05
Return on Invested Capital-10.305.734.554.65
Margins
EBITDA Margin-7.3816.0713.6413.39
Operating Margin-15.408.346.366.36
Incremental Operating Margin-5,921.32-23.42
Pretax Margin-37.890.04-0.54-0.11
Net Income Margin-43.990.04-0.54-0.11
Net Income to Common Margin-44.020.04-0.54-0.11
FCF Margin5.2613.477.317.31
Additional
Effective Tax Rate-16.080.000.00-0.00
Sustainable Growth Rate-60.580.05-0.59-0.59
Incremental Operating Margin %-5,921.32-23.422.91
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.